
Diabetic foot infections
A common and serious complication of diabetes. DFIs can have life-changing consequences for patients and place significant pressure on healthcare systems worldwide.
Antimicrobial resistance (AMR) is one of the greatest threats to modern medicine, turning once-routine infections into potentially deadly diseases.
NexaBiome Life Sciences is developing products based on natural antimicrobials (bacteriophages or phages) to treat drug-resistant bacterial infections.

people a year could die due to AMR by 2050
cumulative cost of AMR to the global economy
deaths directly attributable to AMR in 2025
phages on the planet, outnumbering all other cellular life combined
Antimicrobial resistance (AMR) is putting modern medicine at risk. As infections become harder to treat, healthcare systems worldwide need new antimicrobial approaches.


Bacteriophages, or phages, are natural bacterial killers. They offer a fundamentally different way to target bacterial infections.
NexaBiome Life Sciences is developing technologies that overcome key barriers that have limited phage development, helping turn phages into practical antimicrobial products.


A common and serious complication of diabetes. DFIs can have life-changing consequences for patients and place significant pressure on healthcare systems worldwide.

NexaBiome Life Sciences is using its patented technology to develop a wound dressing that targets Staphylococcus aureus, a key pathogen in diabetic foot infections.
Combining an urgent unmet need with differentiated technology and a commercially focused development strategy.